Clinical Trial Suggests Genetic Signatures Could Guide Non-Small Cell Lung Cancer Drug Response | GenomeWeb
NEW YORK (GenomeWeb News) – New research suggests that advanced lung cancer patients with certain genetic signatures respond to an experimental cancer drug as a first line of defense.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.